top of page
Browse by category
Search
Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity
The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...
BioAge axes STRIDES trial evaluating azelaprag in combination with tirzepatide for the treatment of obesity
BioAge Labs is to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in...
Introducing XNY Medical’s next-generation ENDO NOVA Powered Stapler
Bariatric News talked to Dr Jassim Fakhro, Senior Consultant in General, Metabolic, Bariatric and Robotic Surgery, Vice President of the...
LUCIDITY trial to assess Avexitide in post-bariatric hypoglycaemia patients
Amylyx Pharmaceuticals plans to initiate a Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class...
Surgical staplers market to reach US$7.29 billion by 2029
The global surgical staplers market is projected to reach US$7.29 Billion by 2029 from US$5.15 billion in 2024 at a compound annual...
Allurion launches AllurionMeds first AI-native compounded GLP-1 program
Allurion Technologies has launched AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss...
Laekna and Eli Lilly to develop ActRIIA antibody for muscle-preserving weight loss in obesity
Laekna Therapeutics has entered a clinical collaboration with Eli Lilly to accelerate the development of LAE102, a novel Activin Receptor...
GT Metabolic Solutions carries out the first magnetic compression anastomosis cases in the US with the linear magnet technology - the MagDI System
GT Metabolic Solutions has completed the first magnetic compression anastomosis cases in the US using the MagDI System, the procedures...
Endevica Bio spins off new company Abisati to develop weight loss drug
Endevica Bio is to spin-off of a newly created company called Abisati to develop an oral weight loss treatment that has shown efficacy in...
GT Metabolic's MagDI System for side-to-side DI anastomosis to "revolutionise industry" after FDA approval
GT Metabolic Solutions has received FDA clearance of its MagDI System for side-to-side duodeno-ileal (DI) anastomosis. The MagDI System...
Browse by tag
bottom of page